NovoCure (NVCR) Consolidated Net Income (2014 - 2026)

NovoCure has disclosed Consolidated Net Income across 13 years of filings, most recently posting -$71.1 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$71.1 million, down 107.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$173.0 million (down 5.4% YoY), and the FY2025 annual result was -$136.2 million, up 19.21% from the prior year.
• Consolidated Net Income came in at -$71.1 million for Q1 2026 at NovoCure, down from -$24.5 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$4.6 million in Q1 2022 to a low of -$71.1 million in Q1 2026.
• The 5-year median for Consolidated Net Income is -$37.3 million (2022), against an average of -$39.7 million.
• Across the five-year window, Consolidated Net Income slumped 1041.83% in 2023 and soared 62.84% in 2025, its largest moves.
• NovoCure's Consolidated Net Income stood at -$37.3 million in 2022, then dropped by 26.21% to -$47.1 million in 2023, then plunged by 40.02% to -$65.9 million in 2024, then jumped by 62.84% to -$24.5 million in 2025, then tumbled by 190.37% to -$71.1 million in 2026.
• The last three Consolidated Net Income figures came in at -$71.1 million (Q1 2026), -$24.5 million (Q4 2025), and -$37.3 million (Q3 2025), per Business Quant data.